抗体对儿童1型糖尿病中乳糜泻诊断的预测价值
该回顾性纵向分析纳入瑞士2中心2000至2021年诊断的588例儿童1型糖尿病(T1D)患者,共2944个TGA-IgA值,34例(5.8%)随访期间发生乳糜泻(CD)。TGA-IgA约6.1倍正常上限是进行诊断性活检的最佳cutoff;联合IgG抗脱酰胺麦胶蛋白肽抗体曲线下面积达0.79(95%CI 0.6-1),准确率80%。
要点
- TGA-IgA约6.1倍正常上限是平衡敏感性与特异性的最佳活检cutoff。
- 联合IgG抗脱酰胺麦胶蛋白肽抗体曲线下面积0.79(95%CI 0.6-1),准确率80%。
- T1D诊断时TGA-IgA升高可早期识别2年内发生CD的风险个体。
核心结论
- 结果提示TGA-IgA约6.1倍正常上限可作为CD确诊活检的指征。
- 联合IgG抗脱酰胺麦胶蛋白肽抗体可能提高精确性。
- T1D诊断时测定TGA-IgA可能有助于早期识别CD风险个体。
研究设计与样本
- 回顾性纵向分析,纳入瑞士2中心2000至2021年诊断的儿童T1D个体,从T1D诊断随访至CD诊断或18岁。
- 共纳入588例T1D个体,包含2944个TGA-IgA值。
主要发现
- 34例(5.8%)随访期间发生CD,其中50%在CD诊断时伴有CD相关症状。
- TGA-IgA约6.1倍正常上限为平衡敏感性与特异性的最佳活检cutoff。
- 联合IgG抗脱酰胺麦胶蛋白肽抗体曲线下面积0.79(95%CI 0.6-1),准确率80%,高于任一抗体单独使用。
- T1D诊断后2年内发生CD(占CD的三分之二)的特征是T1D诊断时TGA-IgA升高;较晚诊断的CD与TGA-IgA更逐渐升高相关。
关键数值与推荐
- TGA-IgA约6.1倍正常上限为进行诊断性活检的最佳cutoff。
- 联合IgG抗脱酰胺麦胶蛋白肽抗体曲线下面积0.79(95%CI 0.6-1),准确率80%。
临床怎么用
- 作者认为TGA-IgA约6.1倍正常上限可作为CD确诊活检的指征。
- 作者认为联合IgG抗脱酰胺麦胶蛋白肽抗体可能提高精确性。
- 作者认为T1D诊断时测定TGA-IgA可能有助于早期识别CD风险个体。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Children and adolescents with type 1 diabetes (T1D) have a higher risk of developing celiac disease (CD) than the general population. However, the main screening antibody, IgA anti-transglutaminase 2 (TGA-IgA), can fluctuate in T1D and there is no threshold for performing diagnostic biopsies. OBJECTIVES: The study aims to define an optimal TGA-IgA cutoff for performing diagnostic biopsies for CD confirmation and to assess whether tracking TGA-IgA evolution or adding other antibodies can improve biopsy indications. METHODS: Retrospective longitudinal analysis of pediatric T1D individuals diagnosed at 2 centers in Switzerland between 2000 and 2021, from T1D diagnosis to CD diagnosis or the age of 18 years. RESULTS: We included 588 individuals with T1D, comprising 2944 TGA-IgA values. Thirty-four (5.8%) developed CD during follow-up, of whom 50% had CD-associated symptoms at CD diagnosis. Balancing sensitivity and specificity TGA-IgA around 6.1 × upper limit of normal was the best cutoff for performing diagnostic biopsies. The inclusion of IgG antibodies against deamidated gliadin peptides achieved a higher area under the curve of 0.79 (95% CI, 0.6-1) with 80% accuracy compared to each antibody alone. CD diagnosis within 2 years of T1D, representing two thirds of CD, was marked by elevated TGA-IgA at T1D diagnosis. Later CD diagnosis was associated with a more gradual increase of TGA-IgA. CONCLUSION: Our results suggest an indication for biopsy for CD confirmation at a TGA-IgA cutoff around 6.1 × upper limit of normal. Including IgG antibodies against deamidated gliadin peptides can potentially increase precision. TGA-IgA determination at T1D diagnosis may help to identify individuals at risk of CD early on.
引用
- Müller NZ, Muresan IM, Künzi A, et al. Antibodies Are Predictive for Diagnosis of Celiac Disease in Pediatric Type 1 Diabetes. J Clin Endocrinol Metab. 2025. PMID: 40056457. doi:10.1210/clinem/dgaf146
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。